Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 1.598
Filtrar
1.
Washington; Organización Panamericana de la Salud; ago 25, 2020. 28 p.
Não convencional em Espanhol | LILACS (Américas) | ID: biblio-1117908

RESUMO

En el transcurso de la pandemia de COVID-19, numerosos países, de ingresos bajos, medianos y alto, han visto agotadas sus reservas de medicamentos esenciales necesarios para el manejo de los pacientes con COVID-19 en las unidades de cuidados intensivos (UCI). El plan de preparación para emergencias sanitarias de los países requiere incluir una lista de medicamentos esenciales y otros dispositivos médicos necesarios en las UCI para afrontar emergencias sanitarias. La lista de medicamentos esenciales para el manejo de pacientes que ingresan a unidades de cuidados intensivos con sospecha o diagnóstico confirmado de COVID-19 es un documento de orientación fundamental que ayuda a los sistemas de salud de los países a priorizar los medicamentos esenciales que deben estar ampliamente disponibles y ser asequibles para manejar los pacientes en las UCI durante las situaciones de emergencia sanitaria, en este caso con sospecha o diagnóstico confirmado de COVID-19. Está dirigida a las autoridades sanitaras y a los encargados del manejo del sistema de salud de los países. Esta lista incluye fundamentalmente los medicamentos considerados esenciales para el manejo de los cuadros clínicos que con se observan con mayor frecuencia en pacientes hospitalizados en UCI a causa de una infección por SARS-CoV-2. No se incluyen la mayoría de los medicamentos que comúnmente se encuentran en las UCI para el manejo de otras patologías, comorbilidades o la estabilización del paciente (p. ej., insulina o antihipertensivos), salvo aquellos que pueden requerirse para el tratamiento o apoyo (p. ej., bloqueantes neuromusculares o anestésicos) de las dolencias generadas por la infección. Tampoco se incluyen medicamentos específicos para el tratamiento de la infección por SARS-CoV-2, puesto que no existe, por el momento, evidencia científica de alta calidad que avale su uso, salvo en el contexto de ensayos clínicos controlados. Un equipo de expertos en el tema realizó una búsqueda de información sobre la atención de pacientes en UCI durante la pandemia de COVID-19, en Medline (a través de PubMed), Cochrane, Tripdatabase, Epistemonikos y en buscadores generales de internet (Google). Se identificaron también revisiones o guías generadas por ministerios de Salud de varios países de la Región de las Américas, la Organización Mundial de la Salud (OMS), la Organización Panamericana de la Salud (OPS), el Instituto Nacional de Salud y Excelencia Clínica (NICE) de Reino Unido, los Centros para el Control y la Prevención de Enfermedades (CDC) de Estados Unidos y los Institutos Nacionales de Salud (NIH) de Estados Unidos.


Assuntos
Humanos , Criança , Adulto , Pneumonia Viral/tratamento farmacológico , Succinilcolina/uso terapêutico , Antipsicóticos/uso terapêutico , Benzodiazepinas/uso terapêutico , Administração dos Cuidados ao Paciente/organização & administração , Dexametasona/uso terapêutico , Corticosteroides/uso terapêutico , Infecções por Coronavirus/tratamento farmacológico , Medicamentos Essenciais/provisão & distribução , Dexmedetomidina/uso terapêutico , Síndrome Respiratória Aguda Grave/tratamento farmacológico , Antipiréticos/uso terapêutico , Pandemias/prevenção & controle , Betacoronavirus/efeitos dos fármacos , Haloperidol/uso terapêutico , Analgésicos Opioides/uso terapêutico , Unidades de Terapia Intensiva/organização & administração , Anti-Infecciosos/uso terapêutico , Pneumonia Viral/prevenção & controle , Respiração Artificial/enfermagem , Choque Séptico/prevenção & controle , Tromboembolia/prevenção & controle , Infecções por Coronavirus/prevenção & controle , Medicina Baseada em Evidências , Intubação/enfermagem , Hipóxia/tratamento farmacológico
4.
Braz. J. Psychiatry (São Paulo, 1999, Impr.) ; 42(1): 27-32, Jan.-Feb. 2020. tab, graf
Artigo em Inglês | LILACS (Américas) | ID: biblio-1055350

RESUMO

Objective: Patients with schizophrenia have visual processing impairments. The main findings from the literature indicate that these deficits may be related to differences in paradigms, medications, and illness duration. This study is part of a large-scale study investigating visual sensitivity in schizophrenia. Here we aimed to investigate the combined effects of illness duration and antipsychotic use on contrast sensitivity function. Methods: Data were collected from 50 healthy controls and 50 outpatients with schizophrenia (classified according to illness duration and medication type) aged 20-45 years old. The contrast sensitivity function was measured for spatial frequencies ranging from 0.2 to 20 cycles per degree using linear sine-wave gratings. Results: Patients with an illness duration > 5 years had more pronounced deficits. Differences in the combined effects of illness duration and antipsychotic use were marked in patients on typical antipsychotics who had been ill > 10 years. No significant differences were found between typical and atypical antipsychotics in patients with an illness duration < 5 years. Conclusion: Visual impairment was related to both long illness duration and medication type. These results should be tested in further studies to investigate pharmacological mechanisms.


Assuntos
Humanos , Masculino , Feminino , Adulto , Adulto Jovem , Esquizofrenia/tratamento farmacológico , Antipsicóticos/efeitos adversos , Transtornos da Visão/induzido quimicamente , Escalas de Graduação Psiquiátrica , Esquizofrenia/complicações , Fatores de Tempo , Visão Ocular/efeitos dos fármacos , Sensibilidades de Contraste/efeitos dos fármacos , Estudos de Casos e Controles , Clorpromazina/efeitos adversos , Resultado do Tratamento , Pessoa de Meia-Idade
5.
Braz. J. Psychiatry (São Paulo, 1999, Impr.) ; 42(1): 22-26, Jan.-Feb. 2020. tab
Artigo em Inglês | LILACS (Américas) | ID: biblio-1055359

RESUMO

Objective: German psychiatrist Kurt Schneider proposed the concept of first-rank symptoms (FRS) of schizophrenia in 1959. However, their relevance for diagnosis and prediction of treatment response are still unclear. Most studies have investigated FRS in chronic or medicated patients. The present study sought to evaluate whether FRS predict remission, response, or improvement in functionality in antipsychotic-naive first-episode psychosis. Methods: Follow-up study of 100 patients at first episode of psychosis (FEP), with no previous treatment, assessed at baseline and after 2 months of treatment. The participants were evaluated with the standardized Positive and Negative Syndrome Scale (PANSS) and Global Assessment of Functioning (GAF) and for presence of FRS. Results: Logistic regression analysis showed that, in this sample, up to three individual FRS predicted remission: voices arguing, voices commenting on one's actions, and thought broadcasting. Conclusion: Specific FRS may predict remission after treatment in FEP patients. This finding could give new importance to Kurt Schneider's classic work by contributing to future updates of diagnostic protocols and improving estimation of prognosis.


Assuntos
Humanos , Masculino , Feminino , Adulto , Adulto Jovem , Transtornos Psicóticos/diagnóstico , Transtornos Psicóticos/tratamento farmacológico , Esquizofrenia/diagnóstico , Esquizofrenia/tratamento farmacológico , Antipsicóticos/uso terapêutico , Escalas de Graduação Psiquiátrica , Valores de Referência , Indução de Remissão , Modelos Logísticos , Valor Preditivo dos Testes , Seguimentos , Resultado do Tratamento
6.
Braz. J. Psychiatry (São Paulo, 1999, Impr.) ; 41(6): 499-510, Nov.-Dec. 2019. tab, graf
Artigo em Inglês | LILACS (Américas) | ID: biblio-1055341

RESUMO

Objective: To analyze the efficacy and safety of paliperidone palmitate 3-monthly (PP3M) in Latin American patients with schizophrenia vs. rest-of-world (ROW). Methods: We analyzed data from two multinational, double-blind (DB), randomized, controlled phase 3 studies including patients with schizophrenia (DSM-IV-TR) previously stabilized on PP1M/PP3M (open-label [OL] phase). Patients were randomized to PP3M or PP1M (noninferiority study A) and PP3M or placebo (study B) in DB phase. The subgroup analysis included Latin American (Argentina, Brazil, Colombia, Mexico) patients. Primary efficacy endpoints were relapse-free rates (study A) and time-to-relapse (study B). Results: In study A, 63/71 (88.7%) and in study B 38/43 (88.4%) Latin American patients completed the DB phase. In study A, relapse-free percentage was similar in Latin America (PP3M: 97%, PP1M: 100%) and ROW (PP3M: 91%, PP1M: 89%). In study B, median time-to-relapse was not estimable in the Latin American subgroup for either placebo or PP3M groups, nor for the ROW PP3M group; the median time-to-relapse in the ROW placebo group was 395 days. Caregiver burden improved in patients switching from oral antipsychotics (OL baseline) to PP3M/PP1M in DB phase (Involvement Evaluation Questionnaire score mean ± SD change, -9.4±15.16; p < 0.001). Treatment emergent adverse events with PP3M during DB phase were similar in Latin America (study A: 24/34 [70.6%]; study B: 15/21 [71.4%]) and ROW (study A: 318/470 [67.7%]; study B: 84/139 [60.4%]) subgroups. Conclusion: PP3M was efficacious and showed no new safety concerns in patients with schizophrenia from Latin America, corroborating ROW findings. Clinical trial registration: NCT01515423, NCT01529515


Assuntos
Humanos , Masculino , Feminino , Adolescente , Adulto , Idoso , Adulto Jovem , Esquizofrenia/tratamento farmacológico , Antipsicóticos/administração & dosagem , Palmitato de Paliperidona/administração & dosagem , Recidiva , Fatores de Tempo , Efeito Placebo , Método Duplo-Cego , Inquéritos e Questionários , Reprodutibilidade dos Testes , Resultado do Tratamento , Estimativa de Kaplan-Meier , Prevenção Secundária , América Latina , Pessoa de Meia-Idade
7.
Arch. Clin. Psychiatry (Impr.) ; 46(6): 165-168, Nov.-Dec. 2019. tab, graf
Artigo em Inglês | LILACS (Américas) | ID: biblio-1054913

RESUMO

Abstract Objective Schizophrenia is a complex and chronic psychiatric disorder. In recent years, studies have found glutamatergic system participation in its etiopathogenesis, especially through aberrant NMDA receptors functioning. Thus, drugs that modulate this activity, as amantadine and memantine, could theoretically be used in its treatment. To perform a systematic literature review about memantine and amantadine use as adjunct in schizophrenia treatment. Methods A systematic review of papers published in English indexed in the electronic database PubMed ® using the terms "memantine", "amantadine" and "schizophrenia" published until October 2016. Results We found 144 studies, 8 selected for analysis due to meet the objectives of this review. Some of these have shown benefits from such drug use, especially in symptoms measured by PANSS and its subdivisions, while others do not. Discussion: The data in the literature about these drugs use for schizophrenia treatment is still limited and have great heterogeneity. Thus, assay with greater robustness are needed to assess real benefits of these drugs as adjuvant therapy.


Assuntos
Humanos , Esquizofrenia/tratamento farmacológico , Amantadina/uso terapêutico , Memantina/uso terapêutico , Receptores de N-Metil-D-Aspartato/antagonistas & inibidores , Placebos , Escalas de Graduação Psiquiátrica , Antipsicóticos/uso terapêutico , Amantadina/efeitos adversos , Memantina/efeitos adversos , Método Duplo-Cego , Resultado do Tratamento , PubMed , Adjuvantes Anestésicos/uso terapêutico
8.
Horiz. méd. (Impresa) ; 19(3): 78-83, Set. 2019. tab
Artigo em Espanhol | LILACS (Américas), LIPECS | ID: biblio-1022500

RESUMO

En los servicios de emergencias que atienden a una gran población, muchas veces se encuentran cuadros aislados, como deshidratación severa, hipernatremia o hiponatremia, injuria renal aguda, trastorno de sensorio, entre otras. Sin embargo, muchos de estos cuadros forman parte de una sola patología, y si no se hace una unidad clínica en el momento adecuado, la morbimortalidad se puede incrementar drásticamente. Sobre todo, en enfermedades con baja frecuencia, muy raras o poco habituales, como la que se narrará a continuación, podría empeorar el estado crítico del paciente si no se detecta a tiempo o no se maneja adecuadamente. Este caso clínico es el de una paciente mujer de 74 años, con antecedente de patología psicótica con tratamiento irregular que, tras ingerir carbamazepina y risperidona, presenta los síntomas típicos y poco frecuentes del síndrome neuroléptico maligno (SNM).


In emergency rooms with large numbers of assigned population, we often see isolated conditions, such as severe dehydration, hypernatremia or hyponatremia, acute kidney injury, sensory disorder, among others. However, many of these conditions are part of a single disease and, if they are not gathered together as a medical unit at the right time, morbidity and mortality may drastically increase, especially in the event of diseases with a very rare or unusual frequency. Such is the case of the following disorder, which could worsen the critical condition of the patient if it is not detected on time or not treated appropriately. This clinical case addresses a 74-year-old female patient who reports a history of psychotic disorder with irregular treatment and, after the intake of carbamazepine and risperidone, presents the typical and infrequent symptoms of neuroleptic malignant syndrome (NMS).


Assuntos
Humanos , Síndrome Maligna Neuroléptica , Rabdomiólise , Antipsicóticos , Rigidez Muscular
9.
Braz. J. Psychiatry (São Paulo, 1999, Impr.) ; 41(4): 324-335, July-Aug. 2019. tab, graf
Artigo em Inglês | LILACS (Américas) | ID: biblio-1011506

RESUMO

Objective: To present the essential guidelines for pharmacological management of patients with psychomotor agitation in Brazil. Methods: This is a systematic review of articles retrieved from the MEDLINE (PubMed), Cochrane Database of Systematic Reviews, and SciELO databases published from 1997 to 2017. Other relevant articles in the literature were also used to develop these guidelines. The search strategy used structured questions formulated using the PICO model, as recommended by the Guidelines Project of the Brazilian Medical Association. Recommendations were summarized according to their level of evidence, which was determined using the Oxford Centre for Evidence-based Medicine system and critical appraisal tools. Results: Of 5,362 articles retrieved, 1,731 abstracts were selected for further reading. The final sample included 74 articles that met all inclusion criteria. The evidence shows that pharmacologic treatment is indicated only after non-pharmacologic approaches have failed. The cause of the agitation, side effects of the medications, and contraindications must guide the medication choice. The oral route should be preferred for drug administration; IV administration must be avoided. All subjects must be monitored before and after medication administration. Conclusion: If non-pharmacological strategies fail, medications are needed to control agitation and violent behavior. Once medicated, the patient should be monitored until a tranquil state is possible without excessive sedation. Systematic review registry number: CRD42017054440.


Assuntos
Humanos , Agitação Psicomotora/tratamento farmacológico , Antipsicóticos/administração & dosagem , Benzodiazepinas/administração & dosagem , Guias de Prática Clínica como Assunto , Escalas de Graduação Psiquiátrica , Agitação Psicomotora/diagnóstico , Antipsicóticos/classificação , Benzodiazepinas/classificação , Brasil , Gerenciamento Clínico
13.
Rev. gaúch. enferm ; 40: e20180084, 2019.
Artigo em Português | LILACS (Américas) | ID: biblio-1004089

RESUMO

Resumo OBJETIVO Compreender, sob a perspectiva ética de Freire, o cuidado de enfermagem às pessoas com transtorno de personalidade borderline. MÉTODOS Pesquisa qualitativa cuja produção das informações foi realizada de maio a junho de 2016, em duas unidades de internação psiquiátrica. Foram entrevistados sete enfermeiros e oito técnicos de enfermagem. As informações foram analisadas à luz do referencial de Paulo Freire. RESULTADOS Emergiram as categorias: 1) Acolhimento e relacionamento terapêutico como instrumentos para fortalecimento de vínculo; e 2) Terapia medicamentosa e contenção: interface entre proteção, estabelecimento de limites e outros desafios para o cuidado. CONCLUSÕES Os cuidados de enfermagem envolveram tecnologias relacionais, administração de medicamentos e contenção mecânica. Foram referidas dificuldades para lidar com pessoas com esse transtorno. A maneira de cuidar da enfermagem, embora ainda permeada por alguns preconceitos, passa por ideários contidos nos pressupostos éticos que operam à luz da obra de Freire.


Resumen OBJETIVO Comprender, bajo la perspectiva ética de Freire, la atención de enfermería a personas con trastorno límite de la personalidad. MÉTODOS Investigación cualitativa, cuya producción de información se realizó de mayo a junio de 2016, en dos unidades de internación psiquiátrica. Se entrevistaron a siete enfermeras y ocho técnicos de enfermería. Se analizó la información a la luz del marco referencial de Paulo Freire. RESULTADOS Surgieron las categorías: 1) Acogida y relación terapéutica como instrumentos para el fortalecimiento del vínculo; y 2) Terapia medicamentosa y contención: interfaz entre protección, establecimiento de límites y otros desafíos para la atención. CONCLUSIONES La atención de enfermería incluyó tecnologías relacionales, administración de fármacos y contención física. Hubo dificultades para tratar con personas con este trastorno. La forma de cuidar de la enfermería, aunque esté aún impregnada por algunos prejuicios, pasa por ideologías contenidas en los supuestos éticos que operan a la luz de la obra de Freire.


Abstract OBJECTIVE To understand, from the ethical perspective of Freire's, the nursing care for people with borderline personality disorder. METHODS This is a qualitative research whose production of information was conducted from May to June 2016 in two psychiatric admission units. We have interviewed seven nurses and eight nursing technicians. The information was analyzed in the light of Paulo Freire's referential framework. RESULTS The following categories have come up: 1) Welcoming and therapeutic relationship as instruments to strengthen linkage; and 2) Drug therapy and restraint: interface between protection, establishment of limits and other challenges for care". CONCLUSIONS Nursing care involved technologies related, medicine administration and physical restraint. There were difficulties in dealing with this disorder. The way to care for nursing, although still permeated by some prejudices, runs through ideologies contained in the ethical assumptions that operate in the light of Freire's work.


Assuntos
Humanos , Masculino , Feminino , Adulto , Idoso , Adulto Jovem , Transtorno da Personalidade Borderline/enfermagem , Preconceito , Antipsicóticos/uso terapêutico , Restrição Física , Pesquisa Qualitativa , Ética em Enfermagem , Pessoa de Meia-Idade , Relações Enfermeiro-Paciente
15.
Artigo em Coreano | WPRIM (Pacífico Ocidental) | ID: wprim-760321

RESUMO

OBJECTIVES: The current study covers a secondary revision of the guidelines for the pharmacotherapy of schizophrenia issued by the Korean Medication Algorithm for Schizophrenia (KMAP-SCZ) 2001, specifically for co-existing symptoms and antipsychotics-related side-effects in schizophrenia patients. METHODS: An expert consensus regarding the strategies of pharmacotherapy for positive symptoms of schizophrenia, co-existing symptoms of schizophrenia, and side-effect of antipsychotics in patients with schizophrenia was retrieved by responses obtained using a 30-item questionnaire. RESULTS: For the co-existing symptoms, agitation could be treated with oral or intramuscular injection of benzodiazepine or antipsychotics; depressive symptoms with atypical antipsychotics and adjunctive use of antidepressant; obsessive-compulsive symptoms with selective serotonin reuptake inhibitors and antipsychotics other than clozapine and olanzapine; negative symptoms with atypical antipsychotics or antidepressants; higher risk of suicide with clozapine; comorbid substance abuse with use of naltrexone or bupropion/ varenicline, respectively. For the antipsychotics-related side effects, anticholinergics (extrapyramidal symptom), propranolol and benzodiazepine (akathisia), topiramate or metformin (weight gain), change of antipsychotics to aripiprazole (hyperprolactinemia and prolonged QTc) or clozapine (tardive dyskinesia) could be used. CONCLUSION: Updated pharmacotherapy strategies for co-existing symptoms and antipsychotics-related side effects in schizophrenia patients as presented in KMAP-SCZ 2019 could help effective clinical decision making of psychiatrists as a preferable option.


Assuntos
Antidepressivos , Antipsicóticos , Aripiprazol , Benzodiazepinas , Antagonistas Colinérgicos , Tomada de Decisão Clínica , Clozapina , Consenso , Depressão , Di-Hidroergotamina , Tratamento Farmacológico , Humanos , Injeções Intramusculares , Metformina , Naltrexona , Propranolol , Psiquiatria , Esquizofrenia , Inibidores de Captação de Serotonina , Transtornos Relacionados ao Uso de Substâncias , Suicídio , Vareniclina
16.
Artigo em Coreano | WPRIM (Pacífico Ocidental) | ID: wprim-760319

RESUMO

OBJECTIVES: In this preliminary study, we investigated the clinical characteristics of patients who were first diagnosed with psychotic disorder and explored the impact of the adherence to antipsychotics on long-term medical use. METHODS: All national health insurance claims related to psychotic disorders including gender, age, income, and drug compliance, from January 1, 2008 to December 31, 2015, were examined. With trend test using Medication Possession Ratio (MPR), we compared the medical use between the compliant group (MRP≥0.8) and the comparative non-compliant group (0.2≤MPR<0.8). RESULTS: Among 28,095 participants in total, 16,239 patients (57.8%) were diagnosed as schizophrenia; the 30s were the most common (n=7,151, 25.5%). Drug compliance was generally low regardless of the diagnosis and was the lowest among 20s with the 40–60% range of income. The compliant group showed lower psychiatric and medical use than the comparative group in the following years (p<0.0001). CONCLUSION: These findings suggest that patients in the 20s and 30s with the 40–60% range of income, who are diagnosed with schizophrenia at the first psychiatric visit, may need more clinical and political attention. The results also emphasize the importance of initial drug adherence to antipsychotics in reducing long-term psychiatric costs.


Assuntos
Antipsicóticos , Complacência (Medida de Distensibilidade) , Diagnóstico , Humanos , Programas Nacionais de Saúde , Transtornos Psicóticos , Esquizofrenia
17.
Artigo em Inglês | WPRIM (Pacífico Ocidental) | ID: wprim-739462

RESUMO

Rabbit Syndrome is an uncommon side effect of antipsychotic treatment. Although it is usually associated with typical antipsychotics, it can also be related to atypical antipsychotics. Anticholinergics are the most accepted treatment approach in treating Rabbit Syndrome. Fluvoxamine is a member of selective serotonin reuptake inhibitors and it is a potent agonist of sigma 1 receptors. In this article, we report a Rabbit Syndrome case who has benefited from fluvoxamine, in terms of both depressive disorder and Rabbit Syndrome; and present the data on the effects of sigma 1 agonist fluvoxamine on numerous movement disorders.


Assuntos
Antipsicóticos , Antagonistas Colinérgicos , Transtorno Depressivo , Fluvoxamina , Transtornos dos Movimentos , Receptores sigma , Inibidores de Captação de Serotonina
18.
Artigo em Coreano | WPRIM (Pacífico Ocidental) | ID: wprim-738914

RESUMO

OBJECTIVES: Clozapine is the drug of choice in treatment-resistant schizophrenia. However, its use is often delayed and a significant proportion of clozapine treated patients fails to respond and experience potentially dangerous side-effects. The aim of this retrospective study was to describe the clinical characteristics of patients started on clozapine and the rate and reason of discontinuation of clozapine. METHODS: Medical records of 83 patients started on clozapine during the period of 2012–2016 were reviewed. RESULTS: Clozapine started on patients in chronic phase; the mean age of start was 38.1 years old and the mean number of psychiatric admission was 6.5. A majority (80.7%) of the patients had been subjected to antipsychotic polypharmacy prior to clozapine and most (61.5%) of them were being treated with polypharmacy including clozapine. Overall, 39 (47.0%) subjects had continued clozapine whereas 15 (18.1%) discontinued it; 29 (34.9%) were lost to follow-up. The most common reason for discontinuation was side-effects (n=13) including six life-threatening cases, most of which occurred within 6 months of its start. CONCLUSION: This study demonstrated that there is some evidence of delays to clozapine use, high rates of polypharmacy and significant rate of discontinuation during the early phase of clozapine treatment.


Assuntos
Antipsicóticos , Clozapina , Humanos , Perda de Seguimento , Registros Médicos , Polimedicação , Estudos Retrospectivos , Esquizofrenia
19.
Artigo em Coreano | WPRIM (Pacífico Ocidental) | ID: wprim-787412

RESUMO

OBJECTIVES: The present study is to investigate inflammatory markers and associated clinical factors between treatment resistant schizophrenia and non-treatment resistant schizophrenia.METHODS: Of the 116 schizophrenia subjects who were hospitalized for ac ute symptomatic treatment, 19 patients (16%) were treated with clozapine as a treatment resistant schizophrenia(TRS) and 97 patients(84%) were treated with other atypical antipsychotics as a non-treatment resistant schizophrenia(Non-TRS). Various inflammatory markers including C-reactive protein(CRP) and clinical factors were retrospectively evaluated with electrical medical records.RESULTS: There were significant differences between two groups in disease duration(p =0.015), number of admission (p =0.003), Clinical Global Impression(p <0.001) but other demographic and clinical variables including previous antipsychotics use did not show significant differences. In terms of hematologic profiles, TRS group demonstrated higher CRP level(p =0.006), lower neutrophil count(p =0.012), and lower hemoglobin level(p =0.003) compared with non-TRS group. Body mass index was significantly correlated with CRP(r=0.318, p =0.001).CONCLUSION: The elevated level of serum CRP in TRS suggests that treatment resistance in schizophrenia may be associated with inflammatory response. However, retrospective study design and small number of subjects could limit this interpretation.


Assuntos
Antipsicóticos , Índice de Massa Corporal , Proteína C-Reativa , Clozapina , Humanos , Registros Médicos , Neutrófilos , Estudos Retrospectivos , Esquizofrenia
20.
Braz. J. Pharm. Sci. (Online) ; 55: e17825, 2019. tab, graf
Artigo em Inglês | LILACS (Américas) | ID: biblio-1039074

RESUMO

Antipsychotic Drugs (APDs) are being widely prescribed to treat various disorders, including schizophrenia and bipolar disorder; however, abnormal glucose metabolism and weight gain have been reported with Atypical Anti-Psychotic drugs (AAPDs) that can lead to insulin-resistance and type 2 diabetes mellitus. The study was designed to assess various biochemical parameters including insulin and blood sugar before and after exposure to APDs in order to exclude the involvement of psychiatric disorders and certain other factors in metabolic dysregulations. Fifty seven APDs-naïve patients with first episode psychosis were divided into six groups who received olanzapine, quetiapine, risperidone, aripiprazole, haloperidol or combination of olanzapine with escitalopram and haloperidol. The serum samples were taken before the intake of the first dose and then on follow-up. Decrease in the level of elevated insulin and glucose was observed post-treatment in some patients, while others were observed whose insulin and glucose levels increased post-treatment, yet some patients did not show any disturbance in the insulin and glucose levels. It is concluded that psychiatric disorders by itself, narcotics, cigarette smoking and use of oral snuff may be also be implicated in metabolic dysregulations. The effects of APDs on insulin and glucose in healthy volunteers might be different than in patients with psychiatric disorders.


Assuntos
Humanos , Masculino , Feminino , Adolescente , Antipsicóticos/análise , Antipsicóticos/efeitos adversos , Glucose/efeitos adversos , Insulina/efeitos adversos , Pâncreas/efeitos dos fármacos , Análise de Variância , Risperidona/efeitos adversos , Fumarato de Quetiapina/efeitos adversos , /efeitos adversos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA